Eli Lilly (LLY) Other Accumulated Expenses (2009 - 2026)

Eli Lilly (LLY) has 18 years of Other Accumulated Expenses data on file, last reported at $8.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 130.75% year-over-year to $8.7 billion; the trailing twelve-month figure through Mar 2026 stood at $8.7 billion (up 130.75% YoY), and the FY2025 full-year result was $8.5 billion, up 32.2% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $8.7 billion, up from $8.5 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $8.7 billion in Q1 2026 and bottomed at $2.0 billion in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $3.8 billion (2025), against an average of $4.2 billion.
• The widest annual swing landed in 2022, when Other Accumulated Expenses decreased 23.67%; it then soared 130.75% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $2.8 billion in 2022, then advanced by 15.32% to $3.3 billion in 2023, then soared by 94.95% to $6.4 billion in 2024, then jumped by 32.2% to $8.5 billion in 2025, then increased by 2.86% to $8.7 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $8.7 billion (Q1 2026), $8.5 billion (Q4 2025), and $5.2 billion (Q3 2025), per Business Quant data.

Peer Comparison